CVS Health announced plans to split itself into two public companies, unwinding the $69 billion Aetna acquisition. One entity will include Aetna, Caremark, CVS Specialty, Oak Street Health and Signify Health. The other, CVS Pharmacy, will include roughly 9,000 stores, mail pharmacy, MinuteClinic and the Health100 technology business. The separation is expected to be completed in the first half of 2028.
CVS is framing the move as a strategic one, giving each business sharper focus, independent capital structures and “greater agility” to respond to “regulatory and other external dynamics.” CEO David Joyner asserted that regulation was not the reason for the split, calling it instead the next step in CVS’s “evolution.” Drug Channels’ Adam Fein views it similarly, arguing that regulatory risks are ”real” but secondary to whether the synergies between retail pharmacies and Caremark actually materialized. On the other hand, media coverage has called the move a “stunning reversal of strategy” and “indictment” of vertical integration.
Despite CVS’ messaging, it is hard to separate CVS’s decision from the regulatory environment around it. Tennessee and Arkansas have enacted laws barring common ownership of pharmacies and PBMs. CVS says those laws would force it to close 134 pharmacies in Tennessee and 23 in Arkansas, and it is challenging both in court.
The push has also become increasingly bipartisan, especially through the Hawley-Warren Patients Before Monopolies Act. The Democrats’ midterm wins mean scrutiny is expected to continue in 2027.
– Megan Hickey, Managing Director